WuXi Biologics (Cayman) Inc. (HKG:2269)

Market Cap	113.71B
Revenue (ttm)	19.87B
Net Income (ttm)	3.57B
Shares Out	4.10B
EPS (ttm)	0.83
PE Ratio	33.23
Forward PE	23.92
Dividend	n/a
Ex-Dividend Date	n/a

Volume	64,203,274
Average Volume	53,658,138
Open	26.30
Previous Close	26.20
Day's Range	25.65 - 28.10
52-Week Range	10.14 - 28.85
Beta	0.73
RSI	65.82
Earnings Date	Mar 21, 2025

About WuXi Biologics

WuXi Biologics (Cayman) Inc., an investment holding company, provides end-to-end solutions and services for biologics discovery, development, and manufacturing for biologics industry in the People’s Republic of China, North America, Europe, Singapore, Japan, South Korea, and Australia. It operates through two segments: Biologics and XDC. The company provides a suite of solutions for biologic discovery, from concept to IND, that seamlessly transits to CMC and downstream process development through its contract research, development, and manufact...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2014
• Employees: 12,740
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2269

Financial Performance

In 2024, WuXi Biologics's revenue was 18.68 billion, an increase of 9.63% compared to the previous year's 17.03 billion. Earnings were 3.36 billion, a decrease of -1.28%.

Financial numbers in CNY